Relmada Therapeutics Inc Share

$3.00

0.33%

Nasdaq, Jun 28, 10:00 pm CET

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Relmada Therapeutics Inc Share price

$3.00

-4.42 59.57% 5Y

Nasdaq, Closing price Fri, Jun 28 2024

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key figures

Market capitalization	$90.52m
Enterprise Value	$6.91m
PER (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.26
Turnover (TTM) Turnover	$0.00
EBIT (operating result TTM) EBIT	$-98.54m
Free cash flow (TTM) Free cash flow	$-48.19m
Cash position	$83.61m
EPS (TTM) EPS	$-3.13
P/E ratio expected	negative
Short interest	5.24%

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Relmada Therapeutics Inc Share analysis

Unlock scores for free

??

4 Analysts have issued a Relmada Therapeutics Inc forecast:

2x Buy

50%

1x Hold

25%

1x Sell

25%

More details on analyst estimates including price targets

4 Analysts have issued a Relmada Therapeutics Inc forecast:

Buy

50%

Hold

25%

Sell

25%

Analyst estimates incl. share price targets

Financial data from Relmada Therapeutics Inc

Profit and loss account P&L | Balance sheet | Cash flow

Quarter TTM Annually

Mar '24		+/- %
Turnover	- -	- 100%
- Direct costs	- -	- -
Gross income	- -	- -
- Selling and administrative expenses	46 46	1% 1% -
- Research and development costs	52 52	50% 50% -
EBITDA	-99 -99	35% 35% -
- Depreciation and amortization	- -	- -
EBIT (operating result) EBIT	-99 -99	35% 35% -
Net profit	-94 -94	34% 34% -

Figures in millions USD.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Subscribe to news free of charge

Relmada Therapeutics Inc Share News

Neutral

Accesswire

●

2 days ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Infringements Of Securities Regulations And Encourages Investors Who Experienced Losses To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed ...

Neutral

Accesswire

●

4 days ago

The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Breaches Of Securities Laws And Urges Investors Who Sustained Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed ...

Neutral

Accesswire

●

5 days ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Law Violations And Encourages Investors With Losses To Contact

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed ...

More Relmada Therapeutics Inc News

Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office	United States
CEO	Sergio Traversa
Employees	20
Founded	2012
Website	www.relmada.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

Start now